Track the Chordia Therapeutics株式会社 share price and the full directors' dealings record of the company, a publicly traded company based in Japan. Shares are quoted on the JP market, under the oversight of EDINET (Japan FSA). Market capitalisation: €5.5bn. The latest transaction was reported on 16 September 2026 (Holding update). Among the most active insiders: SBI Investment Co., Ltd.. Every trade is free.
31
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
24Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,358 of 27,626 companies
6.9
score / 100
Value
6
Quality
7
FCF yld-35%
Earn yld-34%
EV/EBITDA·
ROE-56%
Gross mgn-6.6%
Net mgn-8.3%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Chordia Therapeutics es una empresa que cotiza en el mercado XTKS, especializada en el desarrollo de terapias innovadoras. Se centra en la investigación y comercialización de tratamientos para diversas enfermedades.